Pentoxifylline: a drug with wide spectrum applications in dermatology.
Pentoxifylline (PTX) is a methylxanthine derivative with a variety of anti-inflammatory effects. Currently, PTX is approved by the Food and Drug Administration for the treatment of intermittent claudication, but studies have shown that it has a variety of physiological effects at the cellular level, which may be important in treating a diverse group of diseases.
Zargari
Omid
O
Pars Clinic, Rasht, Iran. ozargari@iranderma.com
D000328:Adult; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D006086:Graft vs Host Disease / Q000188:drug therapy; D015658:HIV Infections / Q000188:drug therapy; D018056:Hemorheology / Q000187:drug effects; D006801:Humans; D007223:Infant; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy; D007918:Leprosy / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D010431:Pentoxifylline / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D012507:Sarcoidosis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014652:Vascular Diseases / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000933:Antifibrinolytic Agents; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline